Anvimo 480mg Tablet is an antiviral medication containing letermovir as its active ingredient. It belongs to the pharmacological class of antiviral agents and is specifically classified under cytomegalovirus (CMV) DNA terminase inhibitors. Anvimo 480mg Tablet is primarily used to prevent cytomegalovirus (CMV) infection in patients who have recently undergone an allogeneic hematopoietic stem cell transplant (HSCT) and are at a higher risk of CMV reactivation.
Anvimo 480mg Tablet works by inhibiting the CMV DNA terminase complex, which is crucial for viral replication. It is typically prescribed for CMV-seropositive adult patients post-transplant to reduce the likelihood of viral complications. However, the medication is not a treatment for existing CMV infections.
Patients taking this medication should follow strict safety precautions. It is contraindicated in individuals with known hypersensitivity to letermovir or any of its excipients. Additionally, it is not recommended for use with certain medications due to serious drug interactions. Healthcare professionals advise caution in pregnant or breastfeeding women, individuals with liver impairment, and those consuming alcohol.
Anvimo 480mg Tablet is FDA-approved for the prevention of cytomegalovirus (CMV) infection in adult patients who:
Have undergone allogeneic hematopoietic stem cell transplantation (HSCT)
Are CMV-seropositive, meaning they have previously been exposed to the virus
This medication is used prophylactically and should not be used to treat an active CMV infection.
Anvimo 480mg Tablet functions by blocking the CMV DNA terminase complex, a key component required for viral replication. Unlike conventional antiviral drugs that target DNA polymerase, this medication disrupts viral DNA processing and packaging, ultimately preventing the virus from multiplying and spreading in the body.
By stopping CMV replication early in the process, this drug significantly lowers the risk of CMV disease in transplant recipients. The unique mechanism of action makes it highly effective while reducing the likelihood of cross-resistance seen with other CMV treatments. Due to its targeted action, it is well tolerated with a lower risk of severe toxicity compared to older antiviral medications.
Serious drug interactions can alter the effectiveness of Anvimo 480mg Tablet or increase the risk of side effects. Patients should inform their doctor about all medications, including herbal and over-the-counter drugs, before starting this medication.
Notable Drug Interactions:
Immunosuppressants (e.g., Cyclosporine, Tacrolimus, Sirolimus): Letermovir can increase blood levels of these drugs, requiring dose adjustments.
Statins (e.g., Simvastatin, Atorvastatin): Increased risk of myopathy or rhabdomyolysis when taken together. Avoid co-administration or monitor closely.
Anticonvulsants (e.g., Phenytoin, Carbamazepine): May reduce Anvimo 480mg Tablet effectiveness, requiring alternative options.
Rifampin and St. John’s Wort: These reduce drug efficacy and should be avoided.
Oral Contraceptives: Letermovir may lower the effectiveness of hormonal birth control, necessitating additional contraceptive methods.
The standard advised dosage of Anvimo 480mg Tablet for CMV prophylaxis is 480 mg once a day. However, when used alongside cyclosporine, the dosage is decreased to 240 mg daily to avoid high drug levels. This medication comes in both oral tablet and intravenous (IV) infusion forms. Oral tablets should be taken whole, with or without food, while the IV infusion needs to be given under medical supervision to guarantee accurate dosing and monitoring.
Keep Anvimo 480mg Tablet at room temperature (20-25°C), away from moisture and direct sunlight.
Do not double-dose.
Seek immediate medical attention if an overdose occurs. Symptoms may include severe nausea or irregular heartbeat.
Common Side Effects:
Nausea
Fatigue
Headache
Diarrhea
Abdominal pain
Serious Side Effects:
Irregular heartbeat
Swelling in legs or feet
Unexplained bleeding or bruising
Severe allergic reactions (rash, breathing difficulty)
Patients prescribed Anvimo 480mg Tablet should take it regularly to prevent CMV-related complications post-transplant. Always inform your doctor of any medications or supplements being taken to prevent harmful interactions. Missing doses can reduce the effectiveness of CMV prevention. Additionally, regular liver function tests may be required in certain patients.
Fact Box of ANVIMO 480
Molecule Name: Letermovir
Therapeutic Class: CMV DNA terminase inhibitor
Pharmacological Class: Antiviral agent
Indications:
Prevention of CMV infection in HSCT patients
Disclaimer
At Medfast, we’re dedicated to bringing you accurate, trustworthy, and expert-vetted health information. Our primary goal is to ensure you receive content that you can rely on.
It’s crucial to understand that everything on this website is for general information purposes only. This content is not a substitute for professional medical advice, diagnosis, or treatment. We can’t stress enough the importance of consulting with your own doctor. They are the only ones who can provide tailored advice for your specific health concerns or medication questions.
Please, never ignore or delay seeking professional medical advice because of something you’ve read here. Our fundamental mission is to support and enhance the doctor-patient relationship, not to replace it.
All Substitutes
No related products found.
2000+ products
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
Secure Payment
100% secure and trusted payment protection
Easy Return
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.